All In Biotech

Drug Trial Radar · NCT04962867

NCCH2006/MK010 Trial (FORTUNE Trial)

Multicenter Investigator-initiated Phase II Trial of E7090 in Patients With Advanced or Recurrent Solid Tumor With Fibroblast Growth Factor Receptor (FGFR) Gene Alteration (FORTUNE Trial)

Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Jun 15, 2021

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Lead sponsor
National Cancer Center, JapanGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Eisai Co., Ltd.
First posted
Jul 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including fusion, mutation, amplification).

Conditions

  • Advanced or Recurrent Solid Tumors
  • FGFR Gene Alterations

Interventions

  • E7090Drug

    140 mg of E7090 is orally administered once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Baseline up to 3.5 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Tohoku University Hospital

    Aoba-ku, Sendai, Miyagi, Japan · Recruiting

  • Kyushu University Hospital

    Higashi-Ku, Fukuoka, Japan · Recruiting

  • Hokkaido University Hospital

    Kita-Ku, Sapporo, Hokkaido, Japan · Recruiting

  • Okayama University Hospital

    Okayama, Japan · Recruiting

  • Kyoto University Hospital

    Sakyo-ku, Kyoto, Japan · Recruiting

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan, Japan · Recruiting

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.